Literature DB >> 6192909

In vivo antitumor effects of monoclonal antibodies with different immunoglobulin classes.

M Seto, T Takahashi, S Nakamura, Y Matsudaira, Y Nishizuka.   

Abstract

Monoclonal antibodies were produced against MM46, an MM antigen-positive, ascitic mouse mammary tumor of C3H/He mice, and 14 clones were found to produce antibodies reactive with MM46, but not with an MM antigen-negative MM48 tumor. Among these 14 antibodies, 10 reacted also with lymph node cells of C3H.B6-Ly-6b, Ly-6.2 congenic mice. The antigen defined by the 10 antibodies was provisionally designated MM1, and the one defined by the other 4 was designated MM2. Further analysis of MM1 by antibody binding inhibition assay with 3H-labeled MM1-gamma 2b-1 antibody revealed that 8 of the 10 antibodies as well as monoclonal anti-Ly-6.2 showed significant inhibition. This result indicated that there were more than two antigenic determinants on MM1 antigen. The immunoglobulin class of eight antibodies detecting the same antigenic determinant on MM1 was examined and was found to cover major classes of mouse immunoglobulin (mu, gamma 1, gamma 2a, gamma 2b, gamma 3, and alpha). Therefore, the in vivo effect against MM46 tumor cells by these antibodies was studied by a serological tumor neutralization assay. Tumor cells (4 X 10(5)) were treated with antibodies and then injected s.c. into syngeneic C3H/He mice. Ten days later, the tumor was weighed. gamma 2a antibody showed significant suppression of tumor growth, and both gamma 2b and gamma 1 antibodies also revealed suppression. However, mu, gamma 3, and alpha antibodies did not show any significant effect on the tumor growth. To elucidate the mechanisms of tumor suppression by antibodies, the role of macrophages was studied by the antibody-dependent macrophage-mediated cytotoxicity test. In accordance with the in vivo tumor effects, gamma 2a antibody showed 40 to 60% cytotoxicity up to the concentration of 1 microgram/ml, and both gamma 2b and gamma 1 antibodies were also cytotoxic, although less so than gamma 2a. Neither mu nor alpha antibody showed any significant cytotoxicity. gamma 3 antibody showed very weak cytotoxicity against MM46 tumor cells. Thus, a good correlation was observed between the in vivo antitumor effects and in vitro antibody-dependent macrophage-mediated cytotoxicity activity with regard to each class of immunoglobulin, which suggested that macrophages may play an important role in the in vivo antitumor effect of the antibodies used.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6192909

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Cytotoxicities of two disulfide-bond-linked conjugates of methotrexate with monoclonal anti-MM46 antibody.

Authors:  N Umemoto; Y Kato; T Hara
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  New Ly-6 congenic strains.

Authors:  D Ivanyi; P Demant
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

3.  Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions.

Authors:  M Awwad; P G Strome; S C Gilman; H R Axelrod
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

4.  Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children.

Authors:  K Broliden; E Sievers; P A Tovo; V Moschese; G Scarlatti; P A Broliden; C Fundaro; P Rossi
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

5.  Metastatic dissemination of 3LL variants after treatment with monoclonal antibody to a tumor-associated antigen.

Authors:  A Sacchi; S Kennel; P G Natali; G Tibursi; C A Ghetti
Journal:  Clin Exp Metastasis       Date:  1987-09       Impact factor: 5.150

6.  Selective macrophage activation by muramyldipeptide bound to monoclonal antibodies specific for mouse tumor cells.

Authors:  A C Roche; P Bailly; P Midoux; M Monsigny
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Target-selective cytotoxicity of methotrexate conjugated with monoclonal anti-MM46 antibody.

Authors:  N Endo; Y Takeda; K Kishida; Y Kato; M Saito; N Umemoto; T Hara
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models.

Authors:  H Hara; B K Seon
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

9.  Growth inhibition of experimental glioma grafts by monoclonal antibody treatment.

Authors:  D Stavrou; W Mellert; U Mellert; E Keiditsch; K Bise; P Mehraein
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

10.  Anti-tumour effect of humoral and cellular immunities mediated by a bacterial immunopotentiator, Lactobacillus casei, in mice.

Authors:  N Yasutake; M Ohwaki; M Mutai; Y Koide; T Yoshida
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.